Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma Previously Treated With Chemotherapy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Jul 2017
At a glance
- Drugs Milciclib (Primary)
- Indications Malignant thymoma
- Focus Therapeutic Use
- Sponsors Nerviano Medical Sciences; Tiziana Life Sciences
- 17 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Oct 2017.
- 09 May 2017 "On 20 January 2015, the Company in-licensed milciclib from Nerviano Medical Sciences". Hence, retained both the companies because the trial is active, no longer recruiting.
- 04 May 2017 Planned End Date changed from 1 Mar 2019 to 1 Jun 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History